Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1281-1287

  Gourand, Fabienne ^a   Mercey, Guillaume ^a   Ibazizène, Méziane ^a   Tirel, Olivier ^a   Henry, Joël ^a   Levacher, Vincent ^b   Perrio, Cécile ^a   Barré, Louisa ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIVERSITÉ ET INSA DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE C 11; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1 METHYLQUINOLINIUM 3 CARBOXYLIC ACID TRIFLUROMETHANESULFONATE; N (3 IODOBENZYL) N ' (3 CARBONYL QUINOLINE)GUANIDINE; N (3 IODOBENZYL) N' (1 METHYL 3 CARBONYL 1,4 DIHYDROQUINOLINE)GUANIDINE; N (3 IODOBENZYL) N' (1 METHYL 3 CARBONYL QUINOLINIUM)GUANIDINE TRIFLUROMETHANESULFONATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN HOMOGENATE; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; RADIOCHEMISTRY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MALE; OXIDATION-REDUCTION; QUINOLINIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

EID: 77249172705     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901550z     Document Type: Article

References (31)

1. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Delivery Rev. 1999, 36, 229-254.
2. Prokai, L.; Prokai-Tatrai, K.; Bodor, N. Targeting drugs to the brain by redox chemical delivery systems. Med. Res. Rev. 2000, 20, 367-416.
3. Bodor, N.; Buchwald, P. In Burger's Medicinal Chemistry and Drug Discovery; Wiley-Interscience: NewYork, 2003; Vol. 2, Chapter 15, p 534.
4. Bodor, N.; Prokai, L. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discovery Today 2002, 7, 766-774.
5. Bodor, N.; Farrag, H.; Omar, F. Improved delivery through biological membranes: Preparation and investigation of stable dopamine chemical delivery system samples. Bull. Pharm. Sci. 1993, 16, 175-182.
6. Pop, E.; Loftsson, T.; Bodor, N. Solubilization and Stabilization of a Benzylpenicillin Chemical Delivery System by 2-Hydroxypropyl-β- cyclodextrin. Pharm. Res. 1991, 8, 1044-1049.
7. Vasse, J. L.; Levacher, V.; Bourguignon, J.; Dupas, G. Chiral biomimetic NADH models in the benzo[b]-1,6-naphthyridine series. A novel class of stable, reactive and highly enantioselective NADH mimics. Tetrahedron 2003, 59, 4911-4921.
8. Patteux, C.; Foucout, L.; Bohn, P.; Dupas, G.; Leprince, J.; Tonon, M. C.; Dehouck, B.; Marsais, F.; Papamicael, C.; Levacher, V. Solid phase synthesis of a redox delivery system with the aim of targeting peptides into the brain. Org. Biomol. Chem. 2006, 4, 817-825.
9. Tedjamulia, M. L.; Shrivastava, P. C.; Knapp, F. F., Jr. Evaluation of the brain-specific delivery of radioiodinated (iodophenyl)alkyl-substituted amines coupled to a dihydropyridine carrier. J. Med. Chem. 1985, 28, 1574-1580.
10. Pryma, D.; Divgi, C. Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors. Nucl. Med. Biol. 2008, 35, S1:3-S1:8.
11. Sisson, J. C.; Shapiro, B.; Meyers, L.; Mallette, S.; Mangner, T. J.; Wieland, D. M.; Glowniak, J. V.; Sherman, P.; Beierwaltes, W. H. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J. Nucl. Med. 1987, 28, 1625-1636.
12. Montaldo, P. G.; Lanciotti, M.; Casalaro, A.; Cornaglia-Ferraris, P.; Ponzoni, M. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res. 1991, 51, 4342-4346.
13. Iavarone, A.; Lasorella, A.; Servidei, T.; Riccardi, R.;Mastrangelo, R. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res. 1993, 53, 304-309.
14. Smets, L. A.; Loesberg, C.; Janssen, M.; Metwally, E. A.; Huiskamp, R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989, 49, 2941-2944.
15. Kölby, L.; Bernhardt, P.; Levin-Jakobsen, A. M.; Johanson, V.; Wängberg, B.; Ahlman, H.; Forsell-Aronsson, E.; Nilsson, O. Uptake of metaiodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters. Br. J. Cancer 2003, 89, 1383-1389.
16. Klimek, V.; Stockmeier, C.; Overholser, J.; Meltzer, H.; Kalka, S.; Dilley, G.; Ordway, G. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 1997, 17, 8451-8458.
17. 125I]MIBG uptake and release in different regions of the rat brain. Nucl. Med. Biol. 1990, 17, 511-514.
18. Foucout, L.; Gourand, F.; Dhilly, M.; Bohn, P.; Dupas, G.; Costentin, J.; Abbas, A.; Marsais, F.; Barré, L.; Levacher, V. Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carrier for specific brain delivery. Org. Biomol. Chem. 2009, 7, 3666-3673.
19. Edmont, D.; Rocher, R.; Plisson, C.; Chenault, J. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorg. Med. Chem. Lett. 2000, 10, 1831-1834.
20. Woodward, R. B.; Olofson, R. A. The reaction of isoxazoliumsalts with bases. J. Am. Chem. Soc. 1961, 3, 1007-1009.
21. Woodward, R. B.; Woodman, D. J.; Kobayashi, Y. The reaction of 3-unsubstituted N-arylisoxazolium salts with carboxylic acid anions. J. Org. Chem. 1967, 32, 388-391.
22. Woodman, D. J.; Davidson, A. I. N-Acylation during the addition of carboxylic acids to N-tert-butylacylketenimines and the use of the reagent N-tert-butyl-5-methylisoxazolium perchlorate for peptide synthesis. J. Org. Chem. 1973, 38, 4288-4295.
23. Woodward, R. B.; Olofson, R. A. The reaction of isoxazoliumsalts with nucleophiles. Tetrahedron 1966, 22, 415-440.
24. Woodward, R .B.; Woodman, D. J. Stable enol esters from N-t-butyl-5-methylisoxazolium perchlorate. J. Am. Chem. Soc. 1968, 90, 1371-1372.
25. Shepard, K. L.; Halczenko, W.; Cragoe, E. J. 3,5-Diamino-6- chloropyrazinecarboxylic acid "active esters" and their reactions. Tetrahedron Lett. 1969, 54, 4757-4760.
26. Rogister, F.; Laeckmann, D.; Plasman, P.; Van Eylen, F.; Ghyoot, M.; Maggetto, C.; Liegeois, J.; Geczy, J.; Herchuelz, A.; Delarge, J.; Masereel, B. Novel inhibitors of the sodium-calcium exchanger: benzene ring analogues of N-guanidino substituted amiloride derivatives. Eur. J. Med. Chem. 2001, 36, 597-614.
27. Yamamoto, T.; Hori, M.; Watanabe, I.; Tsutsui, H.; Harada, K.; Ikeda, S.; Ohtaka, H. Structural requirements for potential Na/H exchange inhibitors obtained from quantitative structure - activity relationships of monocyclic and bicyclic aroylguanidines. Chem. Pharm. Bull. (Tokyo) 1997, 45, 1282-1286.
28. + analogues. J. Am. Chem. Soc. 1980, 102, 1092-1098.
29. Mauzerall, D.; Westheimer, F. H. 1-Benzyldihydronicotinamide - a model for reduced DPN. J. Am. Chem. Soc. 1955, 77, 2261-2264.
30. Sample analysis of 3 on LC-MS/MS was found to have a similar MS/MS spectrum to 2. The collision associated fragmentation of 2 produced product ions at 212 and 428 indicating 3→2 oxidation in our conditions.
31. 11C]methyl triflate. Int. J. Radiat. Appl. Instrum., Part A 1992, 43, 1383-1385.